Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Allogene Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $63.0K in total
- Insiders trading
- 1
- Net value
- −$63.0K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Allogene Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Douglas Earl Martin | SVP, General Counsel | 488,267 | Aug 25, 2026 | 2 |
| Roberts Zachary | President and CEO | 581,166 | Jul 6, 2026 | 3 |
| Sato Vicki L | Director | 162,575 | Jun 23, 2026 | 1 |
| Kazam Joshua A | Director | 398,463 | Jun 23, 2026 | 2 |
| Humer Franz B | Director | 307,507 | Jun 23, 2026 | 1 |
| Witte Owen N. | Director | 292,832 | Jun 23, 2026 | 1 |
| Messemer Deborah M. | Director | 107,431 | Jun 23, 2026 | 1 |
| Barrett Elizabeth A. | Director | – | Jun 23, 2026 | 1 |
| Mayo Stephen | Director | 25,328 | Jun 23, 2026 | 1 |
| Yoshiyama Annie | SVP, Finance | 124,517 | Apr 23, 2026 | 2 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer | 195,338 | Apr 2, 2026 | 5 |
| Chang David D | President and CEO | 5,150,599 | Mar 18, 2026 | 2 |
| Belldegrun Arie | Director | 2,236,816 | Feb 4, 2026 | 1 |
| Parker Geoffrey M. | CHIEF FINANCIAL OFFICER | 1,252,795 | Feb 4, 2026 | 2 |
| Moore Timothy L. | Chief Technical Officer | 250,713 | Feb 5, 2025 | 0 |
| Chen Yinlin Jack | SVP, Finance | 88,881 | Aug 14, 2023 | 0 |
| Smith Lillian | VP, Corporate Counsel | 140,390 | Apr 5, 2023 | 0 |
| Schmidt Eric Thomas | Chief Financial Officer | 862,439 | Mar 24, 2023 | 0 |
| Moore Alison | Chief Technical Officer | 672,731 | Mar 24, 2023 | 0 |
| Bhavnagri Veer | General Counsel | 556,049 | Mar 16, 2023 | 0 |
| Amado Rafael | EVP of R&D | 541,946 | Oct 11, 2022 | 0 |
| PF Equity Holdings 2 B.V. | 10% Owner | 0 | Apr 4, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 14, 2022 (view filing) | Jan 12 | 2 days | Belldegrun ArieDirector | PPurchase | +155.0K | $12.60 | +$1.95M | +387.6%195.0K after | |
| Oct 4, 2021 (view filing) | Oct 1 | 3 days | Amado RafaelEVP of R&D and CMO | SSale | −11.5K | $24.35 | −$280.2K | −3.4%323.9K after | |
| Sep 17, 2021 (view filing) | Sep 15 | 2 days | Bhavnagri VeerGeneral Counsel | SSale | −5.00K | $24.77 | −$123.8K | −1.2%421.7K after | |
| Sep 9, 2021 (view filing) | Sep 9 | Same day | Witte Owen N.Director | SSale | −5.00K | $25.54 | −$127.7K | −2.2%221.2K after | |
| Aug 23, 2021 (view filing) | Aug 20 | 3 days | Witte Owen N.Director | SSale | −10.0K | $23.47 | −$234.7K | −4.2%226.2K after | 2 lots |
| Aug 17, 2021 (view filing) | Aug 16 | 1 day | Bhavnagri VeerGeneral Counsel | SSale | −5.00K | $21.00 | −$105.0K | −1.2%421.4K after | |
| Jul 16, 2021 (view filing) | Jul 15 | 1 day | Bhavnagri VeerGeneral Counsel | SSale | −5.00K | $21.55 | −$107.8K | −1.2%421.4K after |